KIAA2012

Across TCGA pan-cancer cohorts, KIAA2012 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated KIAA2012 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher KIAA2012 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KIAA2012 expression acts as an unfavorable survival marker.

LIHC, KIRP, and COAD are the cancer types where KIAA2012 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
KIRP	OS	Median	II,III,IV	0.199	0.771	.030	6	view →
COAD	OS	Median	II,III,IV	0.586	0.852	.006	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

KIAA2012–LIHC (DFS)

Open the LIHC breakdown →